Skip to main content

Cardiff Oncology, Inc 10-Q for FY2026 Q3

Cardiff Oncology, Inc. (CRDF)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Cardiff Oncology, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients. AI summary